Gossamer Bio (NASDAQ: GOSS) links CDO’s 5.8M options to seralutinib FDA timing
Rhea-AI Filing Summary
Gossamer Bio, Inc. (GOSS) reported a Form 4 for Chief Development Officer Caryn Peterson showing a grant of stock options for 5,800,051 shares of common stock on 2026-08-24, at an exercise price of $0.175 per share, expiring on 2036-08-23.
According to the vesting terms, 50% of the option vests upon FDA approval of seralutinib. The remaining 50% then vests in 24 equal monthly installments after that approval, subject to continued service. If FDA approval has not occurred within two years of the grant date, the entire option instead vests in 24 equal monthly installments starting two years after the grant date, also subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Peterson Caryn
Role
Chief Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 5,800,051 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,800,051 shares (Direct)
Footnotes (1)
- F1. 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Key Figures
Option shares granted: 5,800,051 shares
Exercise price: $0.175 per share
Underlying common shares: 5,800,051 shares
+4 more
7 metrics
Option shares granted
5,800,051 shares
Stock Option (Right to Buy) granted on 2026-08-24
Exercise price
$0.175 per share
Conversion or exercise price for the stock option
Underlying common shares
5,800,051 shares
Common Stock underlying the option
Expiration date
2036-08-23
Expiration of the stock option grant
Vesting on FDA approval
50% of option shares
Vests upon FDA approval of seralutinib, subject to continuous service
Post-approval vesting installments
24 installments
1/24th of remaining 50% vests monthly after FDA approval
Alternative vesting start
Two years after grant date
If FDA approval has not occurred by then, vesting begins monthly over 24 months
Key Terms
Stock Option (Right to Buy, underlying security, vesting, FDA approval, +1 more
5 terms
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy"
underlying security financial
"underlying_security_title": "Common Stock"
vesting financial
"shares subject to the option will vest upon FDA approval"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FDA approval medical
"will vest upon FDA approval of seralutinib"
FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
FAQ
Who received the stock option grant reported for GOSS?
The grant was reported for Caryn Peterson, who serves as Chief Development Officer of Gossamer Bio, Inc. The Form 4 lists her as an officer of the company, not a director and not a ten percent owner.
What is the exercise price of the stock options granted in this GOSS Form 4?
The options reported carry an exercise price of $0.175 per share. This price applies to the 5,800,051 shares underlying the stock option described as a “Stock Option (Right to Buy)” in the Form 4.
When do the newly granted GOSS options expire?
The options are scheduled to expire on 2036-08-23. This expiration date applies to the full 5,800,051 shares underlying the stock option grant reported in the Form 4 filing.
How do the GOSS options vest if seralutinib receives FDA approval?
If seralutinib receives FDA approval, 50% of the option vests at that time. The remaining 50% then vests in 24 equal monthly installments after approval, with each vesting date conditioned on Ms. Peterson’s continuous service.
How do the GOSS options vest if FDA approval of seralutinib is delayed more than two years?
If FDA approval has not occurred within two years after the grant date, the entire option vests instead in 24 equal monthly installments beginning after that two-year point, again subject to Ms. Peterson’s continuous service on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
